HER2 Targeted Therapies Market Report 2026

HER2 Targeted Therapies Market Overview

• HER2 Targeted Therapies market size has reached to $10.84 billion in 2025 • Expected to grow to $16.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.6% • Growth Driver: Growing Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Increasing Demand For Precision Oncology And Biomarker-based Cancer Treatments • Market Trend: Innovations In HER2-Mutant Advanced Non-Small Cell Lung Cancer Targeted Therapies Improve Precision Oncology Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under HER2 Targeted Therapies Market?

HER2 targeted therapy is a cancer treatment that specifically blocks the human epidermal growth factor receptor 2 (HER2), a protein that promotes tumor growth. It is mainly used in HER2-positive cancers. These therapies work by binding to the HER2 receptor or inhibiting its signaling pathways to stop cancer cell growth. They are part of precision medicine and often provide more effective and less toxic treatment compared to traditional chemotherapy. The main therapy types of HER2 targeted therapies include monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates. Monoclonal antibodies refer to biologic drugs designed to specifically bind to HER2 receptors to inhibit cancer cell growth. These therapies are used across indication types including breast cancer, gastric cancer, and colorectal cancer and are administered through oral and intravenous routes. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are utilized by end user types including hospitals, oncology clinics, and cancer specialty centers.

What Is The HER2 Targeted Therapies Market Growth Forecast?

The HER2 targeted therapies market size is expected to see strong growth in the next few years. It will grow to $16.34 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rising adoption of precision oncology and biomarker testing, increasing development of next generation adc therapies, expansion of personalized cancer treatment protocols, growing investment in biotechnology and biologics manufacturing, increasing regulatory approvals for targeted oncology drugs. Major trends in the forecast period include expansion of antibody drug conjugates in HER2 positive cancers, increasing adoption of biosimilar HER2 targeted therapies, rising use of combination regimens with chemotherapy and immunotherapy, growth in next generation tyrosine kinase inhibitors, development of biomarker driven personalized oncology treatment pathways.

Global HER2 Targeted Therapies Market Segmentation

1) By Therapy Type: Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Antibody Drug Conjugates 2) By Indication Type: Breast Cancer, Gastric Cancer, Colorectal Cancer 3) By Route Of Administration Type: Oral, Intravenous 4) By Distribution Channel Type: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End User Type: Hospitals, Oncology Clinics, Cancer Specialty Centers Subsegments: 1) By Monoclonal Antibodies: Trastuzumab Based Therapies, Pertuzumab Based Therapies, Margetuximab Based Therapies, Biosimilar Monoclonal Antibodies 2) By Tyrosine Kinase Inhibitors: Lapatinib Based Inhibitors, Neratinib Based Inhibitors, Tucatinib Based Inhibitors, Afatinib Based Inhibitors 3) By Antibody Drug Conjugates: Trastuzumab Emtansine, Trastuzumab Deruxtecan, Next Generation Human Epidermal Growth Factor Receptor Two Antibody Drug Conjugates

What Is The Driver Of The HER2 Targeted Therapies Market?

The growing adoption of personalized medicine is expected to propel the growth of the HER2-targeted therapies market going forward. Personalized medicine refers to a medical approach that tailors treatment strategies based on an individual patient’s genetic profile, biomarker expression, and specific disease characteristics to improve therapeutic outcomes and minimize adverse effects. The growing adoption of personalized medicine is rising due to advancements in genomic and biomarker testing, enabling more precise and effective treatments tailored to individual patient profiles while reducing adverse effects. HER2 targeted therapies support personalized medicine adoption by providing highly specific treatment options for patients with HER2-positive cancers, improving treatment effectiveness and enabling more precise disease management. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based professional membership organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the HER2-targeted therapies market.

Key Players In The Global HER2 Targeted Therapies Market

Major companies operating in the her2 targeted therapies market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AstraZeneca PLC, Novartis AG, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Daiichi Sankyo Company Limited, Celltrion Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Biocon Biopharmaceuticals Pvt. Ltd., Shanghai Henlius Biotech Inc., RemeGen Co. Ltd., Zymeworks Inc., Puma Biotechnology Inc., MacroGenics Inc., Alteogen Inc., Dizal Pharmaceutical Co. Ltd., Mersana Therapeutics Inc., BioAtla Inc.

Global HER2 Targeted Therapies Market Trends and Insights

Major companies operating in the HER2-targeted therapies market are focusing on developing advanced therapies, such as HER2-mutant advanced non-small cell lung cancer targeted therapy, to improve clinical outcomes for patients with HER2-mutant cancers. HER2-mutant advanced non-small cell lung cancer targeted therapy refers to precision treatments that specifically target HER2 gene mutations in advanced NSCLC to improve treatment response and control tumor progression with greater accuracy. For instance, in February 2026, Boehringer Ingelheim, a Germany-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for HERNEXEOS (zongertinib), the first targeted therapy approved as an initial treatment option for adults with HER2-mutant advanced non-small cell lung cancer (NSCLC). HERNEXEOS is an orally administered, irreversible HER2-selective tyrosine kinase inhibitor designed to specifically target HER2 (ERBB2) mutations while minimizing wild-type EGFR-related toxicities. The therapy demonstrated a 76% objective response rate in the Beamion LUNG-1 clinical trial and offers once-daily oral administration, improved tolerability, and enhanced precision treatment for patients with unresectable or metastatic HER2-mutant NSCLC.

What Are Latest Mergers And Acquisitions In The HER2 Targeted Therapies Market?

In December 2023, Pfizer, Inc., a US-based pharmaceutical company, acquired Seagen, Inc. for a total enterprise value of approximately $43 billion. Through this acquisition, Pfizer aimed to strengthen its oncology franchise by integrating Seagen’s leading antibody–drug conjugate (ADC) platform and its HER2‑targeted ADCs, including those active in HER2‑positive and HER2‑low cancers, into Pfizer’s global commercial and R&D infrastructure. Seagen, Inc. is a US‑based biotechnology company that specializes in antibody-drug conjugate therapies for solid tumors and hematologic malignancies, with a core pipeline including HER2‑targeted ADCs.

Regional Outlook

North America was the largest region in the HER2 targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the HER2 Targeted Therapies Market?

The HER2 targeted therapies market consists of sales of margetuximab, tucatinib, neratinib, and pyrotinib. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the HER2 Targeted Therapies Market Report 2026?

The HER2 targeted therapies market research report is one of a series of new reports from The Business Research Company that provides HER2 targeted therapies market statistics, including HER2 targeted therapies industry global market size, regional shares, competitors with a HER2 targeted therapies market share, detailed HER2 targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the HER2 targeted therapies industry. This HER2 targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.